• News
  • SAN DIEGO
  • General

Trovagene names new member to its scientific advisory board

San Diego-based Trovagene Inc. (Nasdaq: TROV), a developer of transrenal molecular diagnostics, announced Monday that Dr. Paul Billings has joined the company's scientific advisory board.

Billings currently serves as chief medical officer at Life Technologies Corp. (Nasdaq: LIFE). He is also a certified internist and clinical geneticist, and he brings expertise and clinical experience in the areas of genomics and molecular medicine.

“We are honored that Dr. Billings will be collaborating with Trovagene,” said Antonius Schuh, chief executive officer of Trovagene. “He specializes in improving patient care through expanding the use of medically relevant genomic technologies in clinical settings and his expertise is critical he helps shape policy in the rapidly evolving field of genomic medicine.”

Leave Your Comment

Comments are moderated by SDDT, in accordance with the SDDT Comment Policy, and may not appear on this commentary until they have been reviewed and deemed appropriate for posting. Also, due to the volume of comments we receive, not all comments will be posted.

SDDT Comment Policy: SDDT encourages you to add a comment to this discussion. You may not post any unlawful, threatening, defamatory, obscene, pornographic or other material that would violate the law. All comments should be relevant to the topic and remain respectful of other authors and commenters. You are solely responsible for your own comments, the consequences of posting those comments, and the consequences of any reliance by you on the comments of others. By submitting your comment, you hereby give SDDT the right, but not the obligation, to post, air, edit, exhibit, telecast, cablecast, webcast, re-use, publish, reproduce, use, license, print, distribute or otherwise use your comment(s) and accompanying personal identifying and other information you provide via all forms of media now known or hereafter devised, worldwide, in perpetuity. SDDT Privacy Statement.

User Response
0 UserComments

Leave Your Comment

Comments are moderated by SDDT, in accordance with the SDDT Comment Policy, and may not appear on this commentary until they have been reviewed and deemed appropriate for posting. Also, due to the volume of comments we receive, not all comments will be posted.

SDDT Comment Policy: SDDT encourages you to add a comment to this discussion. You may not post any unlawful, threatening, defamatory, obscene, pornographic or other material that would violate the law. All comments should be relevant to the topic and remain respectful of other authors and commenters. You are solely responsible for your own comments, the consequences of posting those comments, and the consequences of any reliance by you on the comments of others. By submitting your comment, you hereby give SDDT the right, but not the obligation, to post, air, edit, exhibit, telecast, cablecast, webcast, re-use, publish, reproduce, use, license, print, distribute or otherwise use your comment(s) and accompanying personal identifying and other information you provide via all forms of media now known or hereafter devised, worldwide, in perpetuity. SDDT Privacy Statement.

Trovagene Inc.

Company Website

11055 Flintkote Ave.
San Diego, CA 92121

Company Trade Data

Stock Symbol Close
Change
Chg %Chg
Volume
52-Week
High Low
TROV
5.41
  -0.11  
- 1.99%
584,459,000
13.58
4.02

Trovagene Inc. Executive(s):

Antonius Schuh

  • Chief Executive Officer

Stephen Zaniboni

  • Chief Financial Officer